Latest Conference Articles

Christopher Granger, MD, Duke University Medical Center also spoke at the European Society of Cardiology COngress 2016 about the issues surrounding patients' tolerability of anticoagulants and other drugs.

Statins should not be physicians' first option in treating all patients at high risk of cardiovascular disease, according to new European treatment guidelines.

An international team looked at oral anticoagulants and decided dabigatran is the best for stroke prevention in non-valvular atrial fibrillation.

Lung cancer patients who develop sinus tachycardia due to some treatments for their cancer can successfully reduce their heart rates with ivabradine, researchers in Romania report.

Pope Francis plans to appear at the ESC Congress 2016 to endorse the group's healthy lifestyle campaign.

Poushali Mukherjea, PhD, Executive Director, Global Medical Affairs, Bristol-Myers Squibb, noted some key takeaways from her team's 19 abstracts slated to be presented at the European Society of Cardiology Congress 2016 (ESC).

While Anti-VEGF medications can be an effective treatment for patients with diabetic macular edema many will not respond to it making steroids the preferred method for care.

While surgeons across the globe have become used to performing procedures with the same equipment as their colleagues there could be some benefit to having tools specifically designed for their individual preferences.

For patients with retinitis pigmentosa the loss of vision can be a difficult consequence of the condition. An implanted device may not give them back the sight they once had but it can provide a chance to see the world around them in a new way.

Researchers set out to see how prevalent sleep problems are in people with age-related macular degeneration (AMD) at the 34th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS 2016) in San Francisco, California.

David Eichenbaum, MD, an ophthalmologist from Florida, presented data from the HARBOR study at the 34th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS 2016) in San Francisco, California.

While it is not yet approved for the treatment of patients with type 1 diabetes recent studies on canagliflozin have shown it could be an option for this patient population.

The field of diabetes care is continually moving forward. Even as data was being presented at this year's meeting of the American Diabetes Association the future was at the forefront of many people's minds in an effort to help these patients even more.

There is no question that hunger can affect a person's life, a recent study looked at the scientific aspect of this discussion and what doctors can do to help patients with this challenge.

The obesity epidemic continues to grow in this country leaving the medical community to find new ways to help this patient population.

A fair amount of women who are diagnosed with gestational diabetes take active measures to lose weight – but what clinical outcomes does that have?

What happens when a patient with type 2 diabetes uses both a potassium (K)-sparing agent and sodium-glucose co-transporter 2 (SGLT2) inhibitor at the same time?

Acknowledging that uncertainty is a key factor in the care and treatment of multiple sclerosis is part of a solution to a problem, finding the best way to deal with that uncertainty is another issue that must be confronted by patients and doctors alike.

From the time a patient is diagnosed with multiple sclerosis there are often more questions than answers for extended periods of time. What that means for their care and management of symptoms is the subject of a recent study.

A recently concluded survey looked at issues most affecting patients with multiple sclerosis that they may not have been willing or able to discuss with health care providers but could help others with the condition in the future.

Even as the number of medications approved to treat relapsing remitting multiple sclerosis continues to grow patients with progressive forms of the condition still await the first approved treatment option to help manage their symptoms.

Research into the inner workings of multiple sclerosis comes in all shapes and sizes including looking at specific parts of the brain. A recent study has looked at the role of the blood brain barrier and how it affects patients with this condition.

Country music artist, Clay Walker – who is well-known for his hit songs “She Won’t Be Lonely Long†and “Live Until I Die" – was diagnosed with a relapsing form of multiple sclerosis (MS) at the age of 26.

While newly approved treatments for multiple sclerosis move away from interferon based medications Rebif continues to be a popular choice after more than a decade in the field.

The treatment of multiple sclerosis requires the work of more than just neurologists and that figures to be the case well into the future as well.

Marijuana and alcohol – studies suggest that one of these substances helps patients with multiple sclerosis while the other can contribute to comorbidities.

Lifestyle factors and multiple sclerosis is a two-way street; but what does that mean for practicing physicians? Allen Bowling, MD, PhD, explains at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis Center (CMSC) in National Harbor, Maryland.

Disease-modifying therapies (DMTs) help reduce relapses in people with multiple sclerosis. While options have expanded, little is known about which one has the greatest effectiveness.